Page last updated: 2024-12-06

coralyne

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Coralyne is a benzophenanthridine alkaloid isolated from the plant Corydalis solida. It exhibits a range of biological activities, including anti-cancer, anti-viral, and anti-inflammatory effects. Its mechanism of action involves inhibiting the activity of topoisomerase I and II enzymes, which are essential for DNA replication and repair. Coralyne is also known to interact with G-quadruplex DNA structures, which are associated with the regulation of gene expression. Due to its promising pharmacological properties, coralyne has been studied extensively for its potential use in the treatment of various diseases. However, its clinical application is limited due to its toxicity and poor bioavailability.'

coralyne: RN given refers to parent cpd; at this time it is not known for which salt NSC-154890 is synonym; structure; DNA topoisomerse antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23307
CHEMBL ID1184668
CHEBI ID104157
SCHEMBL ID278878
MeSH IDM0040757
PubMed CID23306
CHEMBL ID363506
SCHEMBL ID3320097
MeSH IDM0040757

Synonyms (82)

Synonym
BRD-K24443173-311-03-7
DIVK1C_006699
NCI60_042149
NCIMECH_000651
SDCCGMLS-0066682.P001
coralyne
SPECTRUM4_001865
SPECTRUM_001122
38989-38-7
BSPBIO_000442
PRESTWICK3_000431
PRESTWICK2_000431
NCGC00178614-01
2,3,10,11-tetramethoxy-8-methyl-isoquinolino[2,1-b]isoquinolin-7-ium
2,3,10,11-tetramethoxy-8-methylisoquino[3,2-a]isoquinolinium carboxymethanesulfonate
dibenzo[a,g]quinolizinium, 2,3,10,11-tetramethoxy-8-methyl-, chloride, monohydrate
BSPBIO_002535
SPECTRUM5_000430
KBIO3_001755
KBIO2_001602
NCI60_001099
KBIO2_006738
KBIO1_001643
KBIOSS_001602
KBIO2_004170
KBIOGR_002332
PRESTWICK0_000431
SPBIO_002381
PRESTWICK1_000431
SPECTRUM3_000718
SPECPLUS_000603
SPECTRUM2_000605
SPBIO_000510
BPBIO1_000488
2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinolin-7-ium
CHEBI:104157
CHEMBL1184668
SCHEMBL278878
Q27181476
1031265-39-0
STL559061
2,3,10,11-tetramethoxy-8-methylisoquino[3,2-a]isoquinolinium
BBL036682
AKOS037516171
DTXSID201319165
nsc-96349
dibenzo[a, 2,3,10,11-tetramethoxy-8-methyl-, chloride
coralyne chloride
berbinium, 5,6,7,8,13,13a-hexadehydro-2,3,10,11-tetramethoxy-8-methyl-, chloride
5,6,7,8,13,13a-hexadehydro-8-methyl-2,3,10,11-tetramethoxyberbinium chloride
5,6,7,8,13,13a-hexahydro-8-methyl-2,3,10,11-tetramethoxyberbinium
nsc 96349
dibenzo(a,g)quinolizinium, 2,3,10,11-tetramethoxy-8-methyl-, chloride
dibenzo(a,g)quinolizinium, 8-methyl-2,3,10,11-tetramethoxy-, chloride
2,3,10,11-tetramethoxy-8-methyldibenzo(a,g)quinolizinium chloride
8-methyl-2,3,10,11-tetramethoxydibenzo(a,g)quinolizinium chloride
nsc 154891
einecs 254-239-2
NSC96349 ,
nsc154891
nsc-154891
NCGC00094866-02
NCGC00094866-01
SPECTRUM1500861
CHEMBL363506
HMS1921K20
6872-73-7
AKOS024348916
CCG-38524
SCHEMBL3320097
(-)-coralyne chloride hydrate
sr-05000002641
SR-05000002641-1
MS-26783
DTXSID50959832
2,3,10,11-tetramethoxy-8-methylisoquinolino[3,2-a]isoquinolin-7-ium chloride
2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinolin-7-ium;chloride
coralyne (chloride)
HY-118581
CS-0067506
?nsc-154890
(-)-coralyne chloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency19.95260.002014.677939.8107AID1476
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency0.90850.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency10.00000.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
glucocerebrosidaseHomo sapiens (human)Potency7.07950.01268.156944.6684AID2101
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency25.11890.001815.663839.8107AID894
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
DNA polymerase kappa isoform 1Homo sapiens (human)Potency2.81840.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
caspase-1 isoform alpha precursorHomo sapiens (human)Potency3.16230.000311.448431.6228AID900
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Caspase-7Homo sapiens (human)Potency3.98113.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency2.23871.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1316683Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as broadening of G3NH signal by measuring upfield shift at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316685Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as broadening of G4NH signal by measuring upfield shift at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316693Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as upfield shift in compound 16OCH3 signal at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316686Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as broadening of G5NH signal by measuring upfield shift at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316696Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as upfield shift in G4pG5 signal at ligand:DNA molar ratio of 0.25:1 to 2:1 by 1D 31P NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316675Binding affinity to deoxy(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as formation of negative induced CD band at 25 uM by NMR spectroscopic analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316689Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as broadening of T7H6 signal by measuring downfield shift at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316679Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as change in intensity of negative band at 242 nanometer by circular dichroism method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316676Binding affinity to deoxy(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as G3NH/G6NH signal by measuring melting temperature by 1H NMR spectroscopy2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316684Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as broadening of G6NH signal by measuring upfield shift at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316691Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as upfield shift in compound 5OCH3 signal at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316692Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as upfield shift in compound 15OCH3 signal at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316690Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as upfield shift in compound 1OCH3 signal at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316694Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as downfield shift in T2pG3 signal at ligand:DNA molar ratio of 0.25:1 to 2:1 by 1D 31P NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316697Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as upfield shift in G5pG6 signal at ligand:DNA molar ratio of 0.25:1 to 2:1 by 1D 31P NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316688Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as broadening of T7CH3 signal by measuring downfield shift at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316682Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as diffusion coefficient of G3H8 proton signal at ligand:DNA molar ratio of 2 by NMR DOSY method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316687Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as broadening of T2CH3 signal by measuring downfield shift at ligand:DNA molar ratio of 2 by 1D 1H NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316680Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as formation of 3'-flanking guanine at ligand:DNA molar ratio of 2 by 2D 1H-1H NOESY NMR spectroscopy2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316695Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as downfield shift in G6pT7 signal at ligand:DNA molar ratio of 0.25:1 to 2:1 by 1D 31P NMR method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316678Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as change in intensity of positive band at 264 nanometer by circular dichroism method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID1316681Binding affinity to [d(T2G4T)]4 G-quadruplex DNA (unknown origin) assessed as diffusion coefficient of H1/H16 proton signal at ligand:DNA molar ratio of 2 by NMR DOSY method (Rvb = 5.08 10'-10m2/sec)2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Nuclear magnetic resonance studies reveal stabilization of parallel G-quadruplex DNA [d(T
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID243248Ratio of maximum concentration bound and specificity sum for triplex nucleic acids2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Structural selectivity of aromatic diamidines.
AID1131364Binding affinity to calf thymus DNA at 0.033 to 0.995 ligand to DNA ratio by spectrophotometer analysis1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Dimerization of coralyne and its propyl analogue and their association with DNA.
AID395134Binding affinity to poly(dA).poly(dT) DNA assessed as change in melting temperature2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Ligand binding to nucleic acids and proteins: Does selectivity increase with strength?
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (106)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (12.26)18.7374
1990's12 (11.32)18.2507
2000's26 (24.53)29.6817
2010's48 (45.28)24.3611
2020's7 (6.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.22 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index58.35 (26.88)
Search Engine Supply Index2.07 (0.95)

This Compound (41.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews6 (5.71%)6.00%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other99 (94.29%)84.16%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]